Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-02-25FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (NorthStar RxLLC)
FDA approves a supplemental application from NorthStar RxLLC for a generic combination of four amphetamine salts (dextroamphetamine sacchara…
-
FDA approval · 2022-02-25FDA Approved: DYANAVEL XR — Supplemental Application (NextWave Pharmaceuticals, Inc)
The FDA approved a supplemental application for DYANAVEL XR (amphetamine) submitted by NextWave Pharmaceuticals, Inc.
-
FDA approval · 2022-02-25FDA Approved: DEXTROAMPHETAMINE SULFATE — Supplemental Application (Lupin Pharmaceuticals,Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for dextroamphetamine sulfate, a generic stimulant used to treat attention-…
-
FDA approval · 2022-02-25FDA Approved: VYVANSE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for Vyvanse (lisdexamfetamine dimesylate) submitted by Takeda Pharmaceuticals America, expanding or …
-
FDA approval · 2022-02-25FDA Approved: MYDAYIS — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for MYDAYIS, a mixed amphetamine salts product for ADHD, submitted by Takeda Pharmaceuticals America…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-02-25FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII — Supplemental Application (Alvogen Inc.)
FDA approved a supplemental application for Alvogen's mixed amphetamine salts tablets (CII) in multiple strengths, expanding the generic pro…
-
FDA approval · 2022-02-25FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (SUNRISE PHARMACEUTICAL, INC.)
FDA approved a supplemental application for a generic product containing four amphetamine salts (dextroamphetamine saccharate, amphetamine a…
-
FDA approval · 2022-02-25FDA Approved: AMPHETAMINE SULFATE — Supplemental Application (DR. REDDY'S LABORATORIES INC)
FDA approved a supplemental application for Amphetamine sulfate tablets from Dr. Reddy's Laboratories, indicating regulatory approval associ…
-
FDA approval · 2022-02-25FDA Approved: AMPHETAMINE SULFATE — Supplemental Application (Solco Healthcare US, LLC)
FDA approved a supplemental application for Amphetamine Sulfate submitted by Solco Healthcare US, LLC. The approval pertains to the generic …
-
FDA approval · 2022-02-25FDA Approved: AMPHETAMINE SULFATE — Supplemental Application (Epic Pharma LLC)
FDA approved a supplemental application for Amphetamine sulfate filed by Epic Pharma LLC.
-
FDA approval · 2022-02-25FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Supplemental Application (Rhodes Pharmaceuticals L.P.)
FDA approves a supplemental application for a combination of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetam…
-
FDA approval · 2022-02-25FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Camber Pharmaceuticals’ generic product consisting of dextroamphetamine saccharate, amphetam…
-
FDA approval · 2022-02-25FDA Approved: DYANAVEL XR — Supplemental Application (NextWave Pharmaceuticals, Inc)
FDA approved a supplemental application for DYANAVEL XR from NextWave Pharmaceuticals, expanding its labeling. The approval covers updates t…
-
FDA approval · 2022-02-25FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Elite Laboratories, Inc.)
FDA approves Elite Laboratories, Inc.'s supplemental application for a generic product containing four amphetamine salt components (dextroam…
-
FDA approval · 2022-02-25FDA Approved: VYVANSE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for Vyvanse (lisdexamfetamine dimesylate) from Takeda Pharmaceuticals America, Inc., indicating …
-
FDA approval · 2022-02-25FDA Approved: DEXTROAMPHETAMINE SULFATE — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for dextroamphetamine sulfate from SpecGx LLC, approving a generic formulation of the ADHD/narcoleps…
-
FDA approval · 2022-02-25FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva's supplemental application for a formulation comprising four amphetamine salts: dextroamphetamine saccharate, amphetamine …
-
FDA approval · 2022-02-25FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application from Sandoz to add salt forms of dextroamphetamine and amphetamine for a generic product (dextroamph…
-
FDA approval · 2022-02-25FDA Approved: AMPHETAMINE EXTENDED-RELEASE — Supplemental Application (Neos Therapeutics, LP)
The FDA approved a supplemental application for Amphetamine Extended-Release from Neos Therapeutics, LP, representing an additional regulato…
-
FDA approval · 2022-02-25FDA Approved: AMPHETAMINE SULFATE — Supplemental Application (Granules Pharmaceuticals Inc.)
FDA approved a supplemental application for Amphetamine Sulfate submitted by Granules Pharmaceuticals Inc.
-
FDA approval · 2022-02-25FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Oryza Pharmaceuticals Inc.)
FDA approved a supplemental application for a generic mixed amphetamine salts product consisting of dextroamphetamine saccharate, amphetamin…
-
CLINICAL_TRIALS trial_result · 2022-02-25Clinical Trial Update: Improving ADHD Behavioral Care [NA]
Clinical trial update for improving ADHD behavioral care; study completed with posted results.
-
FDA approval · 2022-02-25FDA Approved: DEXTROAMPHETAMINE — Supplemental Application (Cranbury Pharmaceuticals, LLC)
The FDA approved Cranbury Pharmaceuticals' supplemental application for dextroamphetamine (generic) under ANDA 203644, enabling the generic …
-
FDA approval · 2022-02-25FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application from Sun Pharmaceutical to market a generic product containing a combination of dextroamphetamine an…
-
CLINICAL_TRIALS trial_result · 2022-02-18Clinical Trial Update: Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD) [Phase 2]
A Phase 2 trial evaluated driving performance effects of Amphetamine Extended Release Tablets in adults with ADHD; study completed.